BETA: Please send your feedback!
Natera
NTRA:NAS
Biotechnology
$0
SMALL cap
$36.77
(-0.67%)
1.87%
since start of 2019
-19.78
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 2003
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test; Horizon Carrier Screening; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis; Anora Products of Conception; and Non-Invasive Paternity Testing. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| Matthew Rabinowitz, PhD | Chairman, President & Chief Executive Officer | Male |
| Jonathan Sheena | Director & Chief Technology Officer | Male |
| Daniel Rabinowitz | Secretary & General Counsel | Male |
| Mike Brophy, MBA | CFO, Director & Head-Investor Relations | Male |
| Damon Silvestry | Vice President-Operations | Male |
| Michael C. Little, PhD | Senior Vice President-Research & Development | Male |
| Joshua Leichter | Vice President-Legal & Corporate Affairs | Male |
| Cheng-Ho Lin, PhD | Chief Scientific Officer | null |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
Natera - Competitors and Related Companies
How Natera stacks up to its peers in the Biotechnology industry or with competing business segments.
Natera
NTRA:NAS
Biotechnology
$0
SMALL cap
$36.77
(-0.67%)
1.87%
since start of 2019
-19.78
Paratek Pharmaceuticals
PRTK:NAS
Biotechnology
$104.69mm
SMALL cap
$3.15
(0.04%)
-0.43%
since start of 2019
-0.82
Prothena
PRTA:NAS
Biotechnology
$510.48mm
SMALL cap
$12.79
(0.34%)
0.21%
since start of 2019
-6.49
Pluristem Therapeutics
PSTI:NAS
Biotechnology
$55.93mm
MICRO cap
$3.56
(0.00%)
-0.60%
since start of 2019
-1.38
Vertex Pharmaceuticals
VRTX:NAS
Biotechnology
$57.14bn
LARGE cap
$222.21
(1.94%)
0.35%
since start of 2019
26.46